Analysis of Immune Responses in Patients Treated With Vacc-4x Supports Further Development
News Sep 12, 2012
The comprehensive analysis of the Vacc-4x phase II study is providing important insight for further development towards commercialization.
Researchers from the Vaccine Immunotherapy Center at the Lausanne University Hospital presented today immunological data from the phase II study with Vacc-4x during an oral session at the AIDS Vaccine 2012 conference in Boston. Vacc-4x is an investigational vaccine to treat patients with HIV, developed by Bionor Pharma. The data from immunological analysis, which was carried out at the Swiss laboratory, was presented by Kim Ellefsen-Lavoie, CTU (Clinical trials unit) Coordinator, Vaccine and Immunotherapy Center, University Hospital, Lausanne, Switzerland.
The data show that patients carrying a genetic variant (HLA B-35) associated with rapid disease progression of untreated HIV infection are just as likely to respond to Vacc-4x as other patients. This supports Bionor's intention for the vaccine to function across broader patient populations. Complete findings from the analysis will be submitted for publication.
AIDS Vaccine 2012 webcasts all sessions for viewing and archiving within 24 hours of their presentation. Webcast will be available on this page:
"Immunological data from the phase II study with Vacc-4x are providing insight on how this therapeutic vaccine could lead to the observed reduction in viral load," said Professor Giuseppe Pantaleo, MD, Chief of the Division of Immunology and Allergy, University Hospital, Lausanne, Switzerland. "The results from this study will be valuable for the further development towards a potentially new class of HIV treatment and combination therapies."
New Way Found to Boost Immunity in Fighting Cancer and InfectionsNews
Researchers have identified a key new mechanism that regulates the ability of T-cells of the immune system to react against foreign antigens and cancer.READ MORE
Enterome and Nestlé Health Sciences Launch New Diagnostics CompanyNews
Enterome and Nestlé Health Sciences join to create Microbiome Diagnostics Partners, a company that will enable the development and diagnostics for multiple diseases including inflammatory bowel diseases (IBD) and liver diseases.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018